Drug intelligence / Profile preview

JS307

Development stage: Preclinical
Lead developer: Top Alliance Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JS307 is an antibody-drug conjugate (ADC) developed by TopAlliance Biosciences (Junshi Biosciences) that targets Claudin 18.2 (CLDN18.2). It is designed for the treatment of gastrointestinal (GI) malignancies, such as gastric, esophageal, and pancreatic cancers, where Claudin 18.2 is frequently overexpressed. The therapeutic consists of a monoclonal antibody specific to CLDN18.2 conjugated to a cytotoxic payload. Upon binding to the target on the surface of tumor cells, the ADC is internalized, and the payload is released to induce cell death. JS307 is currently in the preclinical or planned stage of development.

Targets

Claudin 18.2

Beyond the preview

Go deeper on JS307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS307.

Explore the full profile